Apr . 24, 2026 14:00 Zurück zur Liste
Human Papillomavirus (HPV) infection is one of the most common viral infections globally and a leading cause of cervical cancer. While high-risk HPV types are directly associated with cancer development, low-risk types are responsible for benign lesions such as genital warts. Therefore, comprehensive detection and genotyping of HPV are essential for accurate diagnosis, effective screening, and long-term patient management.
Der Cowingene HPV 28 Genotyping Detection Kit (flüssig) is an advanced in vitro diagnostic (IVD) solution designed for the qualitative detection and differentiation of 28 HPV genotypes using real-time PCR technology. By combining high-throughput multiplex detection with precise genotyping capability, this kit provides clinicians with detailed and actionable insights for infection assessment and risk stratification.

This detection kit is intended for the qualitative detection of HPV DNA in clinical specimens. It enables simultaneous identification of 28 HPV genotypes, including:
High-risk types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82
Low-risk types: 6, 11, 40, 42, 43, 44, 54, 61, 81, 83
By covering both high-risk and low-risk HPV types, the kit provides a comprehensive view of infection status, enabling clinicians to distinguish between oncogenic risk and benign conditions. The results serve as important auxiliary evidence for cervical cancer screening, diagnosis, and follow-up monitoring.
The kit is validated for use with:
Urine samples
Cervical swabs
This dual-sample compatibility supports both non-invasive screening Und clinical diagnostic sampling, improving patient compliance and enabling wider population coverage. Urine-based testing is especially suitable for large-scale screening programs and self-collection scenarios.
The kit achieves a limit of detection (LoD) of 100 copies/mL across all 28 HPV genotypes. This ensures reliable detection even at low viral loads, supporting early identification of infections.
Validation confirms that the kit shows no cross-reactivity with non-target pathogens, including:
Chlamydia trachomatis
Neisseria gonorrhoeae
Candida albicans
Trichomonas vaginalis
Gardnerella vaginalis
Ureaplasma species and other HPV types not included in the panel
This guarantees highly accurate results and minimizes false positives.

The test performance remains stable in the presence of common interfering substances such as:
Hemoglobin
White blood cells
Cervical mucus
Vaginal care products and lubricants
Antibiotics (e.g., metronidazole)
This ensures consistent results under real clinical conditions.
All HPV genotypes within the assay are independently detected without interference, ensuring accurate multi-target analysis even in co-infection cases.
The kit demonstrates excellent repeatability, with CV ≤ 5% across:
Different days and batches
Different operators and laboratories
Detection Method: Multiplex real-time PCR (8-analysis system)
Detection Channels: FAM, VIC/HEX, ROX, CY5
Detection Coverage: 28 HPV genotypes
Compatible Instruments:
ABI 7500
Roche LightCycler 480
Bio-Rad CFX96
Other open real-time PCR platforms
Storage Conditions: ≤ -20°C
Shelf Life: 18 months
Certification: CE-IVD
These specifications ensure seamless integration into existing laboratory workflows and support large-scale screening operations.
The liquid-based format offers significant advantages:
Enhanced sample preservation, maintaining nucleic acid integrity
Reduced contamination risk, improving result reliability
Uniform sample processing, ensuring consistent detection
Compatibility with automated workflows, enabling high-throughput testing
This makes the kit highly suitable for hospitals, diagnostic laboratories, and public health screening programs.
The kit is compatible with a full range of supporting reagents, including:
DNA/RNA extraction kits
Sample release reagents
Self-collection kits (urine and vaginal)
This enables a standardized, scalable, and efficient diagnostic workflow, from sample collection to final analysis.
Comprehensive 28-type HPV detection (high-risk + low-risk)
High-resolution genotyping for precise clinical assessment
Ultra-high sensitivity (LoD 100 copies/mL) for early detection
Multiple sample compatibility, including non-invasive urine testing
Strong specificity and anti-interference performance
No cross-reactivity or competitive interference
High-throughput capability for large-scale screening
CE-IVD certified, ensuring regulatory compliance
The Cowingene HPV 28 Genotyping Detection Kit (Liquid) represents a significant advancement in molecular diagnostics by offering broad-spectrum HPV detection with detailed genotyping capability. Its ability to simultaneously detect both high-risk and low-risk HPV types provides clinicians with a more complete understanding of infection status.
By combining multiplex PCR technology, high analytical sensitivity, and flexible sampling options, this kit enhances early detection, improves clinical decision-making, and supports effective cervical cancer prevention strategies.
As the demand for comprehensive and scalable diagnostic solutions continues to grow, this HPV 28 genotyping kit stands out as a powerful tool for modern laboratories and global screening programs.
Verwandt PRODUKTE
Rapid HPV 16/18/45 Molecular Detection with NATBox for Targeted Cervical Cancer Screening
NachrichtApr.24,2026High-Sensitivity HPV (2+16) Molecular Detection for Early Cervical Cancer Screening
NachrichtApr.24,2026Comprehensive HPV 15 Genotyping Solution for Accurate Cervical Cancer Risk Assessment
NachrichtApr.24,2026Comprehensive 14-Pathogen STI Detection Solution for Accurate Molecular Diagnosis
NachrichtApr.24,2026Accurate and Reliable HSV-1/2 Molecular Detection for Clinical Diagnosis
NachrichtApr.24,2026